|
Market Data
Revvity, Inc.
Revvity, Inc. is a provider of health science solutions, offering a comprehensive suite of technologies and services to support research, diagnostics, and drug discovery. The company's core business centers around providing instruments, reagents, software, and related services that facilitate genetic testing and analysis. Revvity's offerings are utilized in early detection of genetic disorders, infectious disease testing, and genomic workflows, targeting a diverse customer base including pharmaceutical companies, research institutions, and healthcare providers. With a wide array of branded products and services, Revvity enables critical applications such as newborn screening, oncology research, and immunodiagnostics. Formerly known as PerkinElmer, the company has a long history, dating back to 1937, and is headquartered in Waltham, Massachusetts.
RVTY is currently trading at $93.63, giving Revvity, Inc. a market cap of 10.51B and a P/E ratio of 43.5. Today's range spans $90.64–$94.33, with shares opening at $90.99 and moving down $0.35 (0.4%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 67/100.
Over the past year RVTY has traded between $81.36 and $118.30 - the current price is +15.1% off the 52-week low and -20.9% from the high. 28 analysts cover the stock with a Hold consensus and a mean 12-month target of $115.13 (range $95.00–$140.00), implying upside of +23.0%.
RVTY scores 68/100 (BUY) and is at $93.63 - in the lower half of its 52-week range within its $81.36–$118.30 annual range. Sentiment at 67/100 is bullish. At 10.51B in Healthcare market cap (P/E: 43.5), this large-cap name benefits from a dynamic that mega-caps don't have: the potential for multiple expansion. When a name at this size with bullish momentum catches the attention of large allocators, the re-rating can be rapid and meaningful.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $1.02 | - | - |
| Q4'25 | $1.58 | $1.70 | +7.5% |
| Q3'25 | $1.14 | $1.18 | +3.6% |
| Q2'25 | $1.14 | $1.18 | +3.4% |
| Q1'25 | $0.95 | $1.01 | +6.4% |
| Q4'24 | $1.38 | $1.42 | +3.1% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q1'26 | $705M | - | - |
| Q4'25 | $777M | $772M | -0.6% |
| Q3'25 | - | $699M | - |
| Q2'25 | - | $720M | - |
| Q1'25 | - | $665M | - |
| Q4'24 | - | $730M | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).